ArticleJAMA network open2026

Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients.

May Ee Png et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.